460 research outputs found
Commercial sponge fishing in Libya: Historical records, present status and perspectives
Natural bath sponges (genera Spongia and Hippospongia, Porifera, Demospongiae) have been harvested for millennia to be used as aids to beauty and body tools, in traditional and modem medicine as well as in painting. Recently, a series of severe epidemics have affected Mediterranean commercial sponges fostering the overexploitation of remaining fishing grounds. Furthermore, Mediterranean bath sponges attain the highest prices compared to Caribbean or Indo-Pacific ones but little or no correct information on origin is transferred to the final buyer. A complex network of re-selling activities and the lack of labelling make it almost impossible to track the pathway of sponge trade. Some of the finest Mediterranean natural bath sponges come from Libya. Nevertheless, little information on Libyan sponge banks and trade have been available mostly given the former international ban. Under an Italian-Libyan joint-project it was possible to assess the past and present situation of sponge fishing in Libya, roughly covering a period of 150 years. After rather low production in years 1860-1879, average crop exceeded 40 t/year between 1880 and 1929. The peak was recorded in years 1920-1929 (almost 70 t/year on average). Today Libyan sponge fishery and trade are mostly confined to the eastern area of the country. Less than 10 t/year are currently harvested. According to a preliminary SCUBA diving survey along the Libyan coasts, sponges belonging to the order Dictyoceratida appear to be the most conspicuous sessile invertebrates in the investigated areas. Here, sponges belonging to the genera Ircinia and Sarcotragus (commonly defined "wild sponges" with no commercial value) appear to be more abundant than those belonging to the genera Spongia and Hippospongia. Sustainable approaches to the exploitation of this valuable natural resource such as sponge farming are proposed and discussed. (c) 2007 Elsevier B.V. All rights reserved
Phase II study of lonidamine in metastatic breast cancer.
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA-4). In spite of these improvements, some patients do not achieve any benefit from ICI, and inevitably develop resistance to therapy over time. Tumor microenvironment (TME) might influence response to immunotherapy due to its prominent role in the multiple interactions between neoplastic cells and the immune system. Studies investigating lung cancer from the perspective of TME pointed out a complex scenario where tumor angiogenesis, soluble factors, immune suppressive/regulatory elements and cells composing TME itself participate to tumor growth. In this review, we point out the current state of knowledge involving the relationship between tumor cells and the components of TME in NSCLC as well as their interactions with immunotherapy providing an update on novel predictors of benefit from currently employed ICI or new therapeutic targets of investigational agents. In first place, increasing evidence suggests that TME might represent a promising biomarker of sensitivity to ICI, based on the presence of immune-modulating cells, such as Treg, myeloid derived suppressor cells, and tumor associated macrophages, which are known to induce an immunosuppressive environment, poorly responsive to ICI. Consequently, multiple clinical studies have been designed to influence TME towards a pro-immunogenic state and subsequently improve the activity of ICI. Currently, the mostly employed approach relies on the association of \u201cclassic\u201d ICI targeting PD-1/PD-L1 and novel agents directed on molecules, such as LAG-3 and TIM-3. To date, some trials have already shown promising results, while a multitude of prospective studies are ongoing, and their results might significantly influence the future approach to cancer immunotherapy
Design of Experiments for Screening
The aim of this paper is to review methods of designing screening
experiments, ranging from designs originally developed for physical experiments
to those especially tailored to experiments on numerical models. The strengths
and weaknesses of the various designs for screening variables in numerical
models are discussed. First, classes of factorial designs for experiments to
estimate main effects and interactions through a linear statistical model are
described, specifically regular and nonregular fractional factorial designs,
supersaturated designs and systematic fractional replicate designs. Generic
issues of aliasing, bias and cancellation of factorial effects are discussed.
Second, group screening experiments are considered including factorial group
screening and sequential bifurcation. Third, random sampling plans are
discussed including Latin hypercube sampling and sampling plans to estimate
elementary effects. Fourth, a variety of modelling methods commonly employed
with screening designs are briefly described. Finally, a novel study
demonstrates six screening methods on two frequently-used exemplars, and their
performances are compared
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study
open32noBackground: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR) <1.29 was chosen as the non-inferiority margin. Analyses according to the frequentist and Bayesian approach were planned. Secondary end points included 2-year failure rate and cardiac safety. Results: A total of 1254 patients from 82 centers were randomized (arm A, long: n ¼ 627; arm B, short: n ¼ 626). Five-year DFS is 88% in the long and 85% in the short arm. The HR is 1.13 (90% CI 0.89-1.42), with the upper limit of the CI crossing the non-inferiority margin. According to the Bayesian analysis, the probability that the short arm is non-inferior to the long one is 80%. The 5-year overall survival (OS) is 95.2% in the long and 95.0% in the short arm (HR 1.07, 90% CI 0.74-1.56). Cardiac events are significantly lower in the short arm (risk-ratio 0.33, 95% CI 0.22-0.50, P < 0.0001). Conclusions: This study failed to show the non-inferiority of a shorter trastuzumab administration. One-year trastuzumab remains the standard. However, a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for patients with cardiac events during treatment and for those with a low risk of relapse. Trial Registration: EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.openConte P.; Frassoldati A.; Bisagni G.; Brandes A.A.; Donadio M.; Garrone O.; Piacentini F.; Cavanna L.; Giotta F.; Aieta M.; Gebbia V.; Molino A.; Musolino A.; Ferro A.; Maltoni R.; Danese S.; Zamagni C.; Rimanti A.; Cagossi K.; Russo A.; Pronzato P.; Giovanardi F.; Moretti G.; Lombardo L.; Schirone A.; Beano A.; Amaducci L.; Bajardi E.A.; Vicini R.; Balduzzi S.; D'Amico R.; Guarneri V.Conte, P.; Frassoldati, A.; Bisagni, G.; Brandes, A. A.; Donadio, M.; Garrone, O.; Piacentini, F.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Molino, A.; Musolino, A.; Ferro, A.; Maltoni, R.; Danese, S.; Zamagni, C.; Rimanti, A.; Cagossi, K.; Russo, A.; Pronzato, P.; Giovanardi, F.; Moretti, G.; Lombardo, L.; Schirone, A.; Beano, A.; Amaducci, L.; Bajardi, E. A.; Vicini, R.; Balduzzi, S.; D'Amico, R.; Guarneri, V
Sponge Mass Mortalities in a Warming Mediterranean Sea: Are Cyanobacteria-Harboring Species Worse Off?
Mass mortality events are increasing dramatically in all coastal marine environments. Determining the underlying causes of mass mortality events has proven difficult in the past because of the lack of prior quantitative data on populations and environmental variables. Four-year surveys of two shallow-water sponge species, Ircinia fasciculata and Sarcotragus spinosulum, were carried out in the western Mediterranean Sea. These surveys provided evidence of two severe sponge die-offs (total mortality ranging from 80 to 95% of specimens) occurring in the summers of 2008 and 2009. These events primarily affected I. fasciculata, which hosts both phototrophic and heterotrophic microsymbionts, while they did not affect S. spinosulum, which harbors only heterotrophic bacteria. We observed a significant positive correlation between the percentage of injured I. fasciculata specimens and exposure time to elevated temperature conditions in all populations, suggesting a key role of temperature in triggering mortality events. A comparative ultrastructural study of injured and healthy I. fasciculata specimens showed that cyanobacteria disappeared from injured specimens, which suggests that cyanobacterial decay could be involved in I. fasciculata mortality. A laboratory experiment confirmed that the cyanobacteria harbored by I. fasciculata displayed a significant reduction in photosynthetic efficiency in the highest temperature treatment. The sponge disease reported here led to a severe decrease in the abundance of the surveyed populations. It represents one of the most dramatic mass mortality events to date in the Mediterranean Sea
Neue linguistische Methoden und arbeitstechnische Verfahren in der Erschliessung der ägyptischen Grammatik
15 páginas, 1 tabla, 6 figuras.Does diversity beget diversity? Diversity
includes a diversity of concepts because it is linked to
variability in and of life and can be applied to multiple
levels. The connections between multiple levels of
diversity are poorly understood. Here, we investigated
the relationships between genetic, bacterial, and
chemical diversity of the endangered Atlanto-Mediterranean sponge Spongia lamella. These levels of
diversity are intrinsically related to sponge evolution
and could have strong conservation implications. We
used microsatellite markers, denaturing gel gradient
electrophoresis and quantitative polymerase chain
reaction, and high performance liquid chromatography to quantify genetic, bacterial, and chemical
diversity of nine sponge populations. We then used
correlations to test whether these diversity levels
covaried. We found that sponge populations differed
significantly in genetic, bacterial, and chemical
diversity. We also found a strong geographic pattern
of increasing genetic, bacterial, and chemical dissimilarity with increasing geographic distance between
populations. However, we failed to detect significant
correlations between the three levels of diversity
investigated in our study. Our results suggest that
diversity fails to beget diversity within a single species
and indicates that a diversity of factors regulates a
diversity of diversities, which highlights the complex
nature of the mechanisms behind diversityResearch funded by grants from the Agence Nationale de la
Recherche (ECIMAR), from the Spanish Ministry of Science
and Technology SOLID (CTM2010-17755) and Benthomics
(CTM2010-22218-C02-01) and the BIOCAPITAL project
(MRTN-CT-2004-512301) of the European Union. This is a
contribution of the Consolidated Research Group ‘‘Grupo de
Ecologı´a Bento´nica,’’ SGR2009-655.Peer reviewe
- …